Obstetrics and Gynecology
Vulvovaginal Disorders: Introduction to Noninfectious Vulvovaginal Diseases
1. What every clinician should know
Pruritus and pain are two of the most common presenting symptoms in women with vulvovaginal disorders. Pruritus and irritation can occur in the presence of obvious dermatologic changes or in conditions with few visible skin changes. Vulvovaginal pain or discomfort can arise in the number of settings, some with obvious clinical signs (e.g., infections such as candidaisis or bacterial vaginosis, inflammation such as lichen planus, neoplasia such as VIN or squamous cell cancer of the vulva, or neurologic disorders such as postherpetic neuralgia) and others in the absence of visible findings (e.g., vulvodynia)
Risk factors depend on the condition diagnosed. Women with lichen simplex chronicus (also termed squamous cell hyperplasia) are more likely to report a history of atopic disease. Women at risk for the development of well-differentiated or simplex vulvar intraepithelial neoplasia include those with a history of lichen sclerosus, while those with poorly-differentiated VIN share risk factors for acquisition of HPV infection (e.g., sexual behaviors such as number of lifetime partners as well as smoking). Immunosuppression also increases risk of certain vulvovaginal disorders including candidiasis and lower anogenital tract intraepithelial neoplasia.
Vulvar symptoms are common, often chronic and can interfere significantly with women's sexual function and sense of well-being. Remaining aware of the differences in epithelial and glandular structure, hormonal responsiveness, neural distribution and immune responses that results from the differences in origin is crucial in assessing and successfully managing vulvar symptoms. The importance of a thorough patient history and careful physical examination are critical in the assessment of vulvar disorders and help to direct the appropriate use of additional testing and choice of management options.
Copyright © 2017, 2014 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models